CHICAGO, 23. August 2024 /PRNewswire/ — Die Alzheimer’s Association begrüßt die heutige Entscheidung der britischen Arzneimittelbehörde MHRA (Medicines and Healthcare Products Regulatory Agency), Leqembi® (Lecanemab) für die Behandlung der Alzheimer-Krankheit zuzulassen. Während wir…
This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.